In June Vivek Ramaswamy, a 29-year-old former hedge fund partner, canceled his honeymoon plans to hike in the French and Swiss Alps. He instead brought his new bride to stand beside him as he rang the bell of the New York Stock Exchange to launch the biggest initial public offering in the history of the American biotechnology industry. What could be more romantic than a few hundred million in paper gains in a single day?

Ramaswamy’s Bermuda-based company, Axovant Sciences, had been formed only eight months earlier, but here it was raising $360 million to develop an Alzheimer’s drug that had been all but abandoned by giant pharma GlaxoSmithKline. On the first day of trading the stock almost doubled, giving Axovant a market capitalization of nearly $3 billion. Considering that Ramaswamy had persuaded Glaxo to part with the unproven remedy for a mere $5 million up front, the newlyweds were ecstatic, as was a veritable wedding party of hedge fund pals who had followed Ramaswamy into the stock.

When "my friend" was in grad school in kiashland not long ago, nearly all his classmates were from India and China, while only 5% were "white". This is an indication of the face of the corporate world in the next few years.

He must have enrolled in some cheap college.

They said so about the Chinese